Company intelligence / Profile preview

Curadis

Ownership: Private
Development stage: Other

Overview

Curadis GmbH is developing steroidal small molecule drugs for oncology indications, with a focus on breast cancer. Its lead asset is a transdermal formulation of 4-hydroxytestosterone (CR1447), which acts as an aromatase inhibitor and androgen receptor modulator. In a Phase II trial (SAKK 21/12), CR1447 was evaluated in patients with metastatic estrogen receptor-positive and AR-positive triple-negative breast cancers.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

4-hydroxytestosterone

Beyond the preview

Go deeper on Curadis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curadis.

Explore the full profile